$VTRS News

Should Value Investors Buy Viatris (VTRS) Stock?

Should Viatris’ Japan IgA Nephropathy Win and New Loan Shape VTRS Investors’ Next Move?

Viatris (VTRS) Secures Loan Amid Positive Phase 3 Results

Viatris (VTRS): Most Undervalued NASDAQ Stocks to Buy Right Now

Viatris (VTRS) is a Great Momentum Stock: Should You Buy?

Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026

Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy

Viatris’ VR‑205 Phase 3 Trial in Japan Met Primary and Key Secondary Endpoints; Safety Profile Aligned With Global Studies, NDA Filing Planned by End‑2026

Are Investors Undervaluing Viatris (VTRS) Right Now?

How Is Viatris’ Stock Performance Compared to Other Healthcare Stocks?

Viatris Recognized as One of the 2026 Best Workplaces™ in Canada

Viatris (VTRS) Stock And The 58% Undervaluation Debate After A Strong Year Of Returns

Viatris Euro Debt Raise Reshapes Capital Structure And Valuation Story

3 Generic Drug Stocks to Watch as New Growth Drivers Emerge

Assessing Viatris (VTRS) Valuation After FDA Review Acceptance For Fast Acting Non Opioid Meloxicam

Viatris (VTRS): Buy, Sell, or Hold Post Q1 Earnings?

Acute Myocardial Infarction Market is Expected to Hit Growth Stride at a CAGR of 13% During the Forecast Period (2026-2036) with New Therapeutic Innovations | DelveInsight

FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy

1 Stock Under $50 to Target This Week and 2 We Avoid

5 Revealing Analyst Questions From Viatris’s Q1 Earnings Call